Made In China
Has any government agency taken action against Made In China over GLP-1 drugs?
Made In China is named in 2 actions in this index: Connecticut Attorney General, settlement agreement, May 6, 2026; Connecticut Attorney General, civil investigative demand (an investigation, not a finding), May 21, 2025. Of the FDA GLP-1 warning letters and openFDA recall reports in this index as of Nov 15, 2026, none is addressed to a firm under this name.
FDA records were matched by exact name only. A firm can appear in FDA records under a different legal name.
- Names in the releases
- Made In China; Made-in-China
- Actions in this index
- 2
- Latest release
- May 6, 2026
Records
| Release | ||||
|---|---|---|---|---|
| May 6, 2026 | Connecticut Attorney General | Settlement agreement | GLP-1 drugs (no ingredient named for this firm) | portal.ct.gov |
| May 21, 2025 | Connecticut Attorney General | Civil investigative demand (an investigation, not a finding) | Semaglutide, Tirzepatide | portal.ct.gov |
What each release says
- Connecticut Attorney General, May 6, 2026, “Attorney General Tong Announces Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales”: “Made-in-China cooperated with the investigation and has now entered into a settlement agreement with Connecticut that prohibits manufacturers from using the platform to advertise or sell GLP-1s to customers in the United States.”
- Connecticut Attorney General, May 21, 2025, “Attorney General Tong Sues GLP-1 Weight Loss Drug Distributor Triggered Brand”: “Attorney General Tong has also issued a Civil Investigative Demand to Made In China, a Chinese international trade platform that advertises and sells "research grade" GLP-1s to United States consumers as injectable weight loss medications.” An investigative demand asks for information; the release does not report a finding.
Other firms named in the same releases are listed on the enforcement page.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- Connecticut Attorney General: Attorney General Tong Announces Online Platform to Cease Bootleg GLP-1 Weight Loss Drug Sales
- Connecticut Attorney General: Attorney General Tong Sues GLP-1 Weight Loss Drug Distributor Triggered Brand
Records last pulled Nov 15, 2026. Every entry links to the original public record.